Journal of Surgery Concepts & Practice >
Effect of preoperative immunoinflammatory response on prognosis in patients undergoing liver transplantation for primary biliary cholangitis: a two-center retrospective study
Received date: 2022-01-17
Online published: 2022-06-16
Objective To observe the effect of liver transplantation in the treatment of primary biliary cholangitis (PBC) and prognosis. Methods The clinical data of PBC patients treated with liver transplantation from January 2001 to December 2020 in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and Shanghai Changzheng Hospital were analyzed retrospectively. A total of 10 preoperative parameters for immunoinflammatory response including systematic immunoinflammatory index, fibrinogen, the ratio among neutrophil, lymphocyte, monocyte, platelet, aspartic aminotransferase, CD4 and CD8 were used to reflect immunoinflammatory response. Score was calculated with monocyte-lymphocyte ratio and fibrinogen. There were higher risk group according to the score ≥-0.12 and lower risk group according to the score <-0.12. Survival rate was analyzed using life table method, and multivariate analysis was done with Logistic regression model and COX regression. Results Totally, 82 patients were enrolled. Postoperative follow-up was performed until to December 31, 2021 with a median 4.54 years follow-up from 2 day to 17.06 year. Survival rate of 1-, 3-, 5-, 10-, and 15-year of 82 patients with PBC after liver transplantation were 85%, 79%, 79%, 79%, 47%, respectively, with survival time of 12.92 years. Multivariate analysis of PBC patients after liver transplantation using preoperative index showed that aspartate aminotransferase-to-platelet ratio was an independent risk factor for 90-day survival(P=0.013), and monocyte-to-lymphocyte ratio with fibrinogen were independent risk factors for postoperative length of stay(P=0.002; P=0.007). Both hospitalization cost and length of stay in higher risk group was significant more than those in lower risk group. Conclusions Pre-operative immunoinflammatory response may affect the short-term prognosis of patients with PBC after liver transplantation.
ZHANG Lei, MAO Jiaxi, LI Tao, TENG Fei, SUN Keyan . Effect of preoperative immunoinflammatory response on prognosis in patients undergoing liver transplantation for primary biliary cholangitis: a two-center retrospective study[J]. Journal of Surgery Concepts & Practice, 2022 , 27(02) : 158 -164 . DOI: 10.16139/j.1007-9610.2022.02.014
| [1] | Palmer M, Regev A, Lindor K, et al. Consensus guidelines: best practices for detection, assessment and ma-nagement of suspected acute drug‐induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease[J]. Aliment Pharmacol Ther, 2020, 51(1):90-109. |
| [2] | Kaplan MM, Gershwin ME. Primary biliary cirrhosis[J]. N Engl J Med, 2005, 353(12):1261-1273. |
| [3] | Lindor KD, Gershwin ME, Poupon R, et al. Primary bi-liary cirrhosis[J]. Hepatology, 2009, 50(1):291-308. |
| [4] | Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review[J]. J Hepatol, 2012, 56(5):1181-1188. |
| [5] | Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis[J]. Lancet, 2015, 386(10003):1565-1575. |
| [6] | Selmi C, Bowlus CL, Gershwin ME, et al. Primary biliary cirrhosis[J]. Lancet, 2011, 377(9777):1600-1609. |
| [7] | 张奉春, 王立, 帅宗文, 等. 原发性胆汁性胆管炎诊疗规范(2021)[J]. 中华内科杂志, 2021, 60(8):709-715. |
| [8] | Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148(4):751-761, e758. |
| [9] | Pratt DS. Primary biliary cholangitis-a new name and a new treatment[J]. N Engl J Med, 2016, 375(7):685-687. |
| [10] | Kuiper EMM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid[J]. Gastroenterology, 2009, 136(4):1281-1287. |
| [11] | Mao JX, Guo WY, Guo M, et al. Acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients[J]. Hepatol Int, 2020, 14(3):347-361. |
| [12] | Mao JX, Teng F, Liu C, et al. Immunometabolic inflammation and hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(3):298-300. |
| [13] | Leung KK, Deeb M, Hirschfield GM. Review article: pathophysiology and management of primary biliary cholangitis[J]. Aliment Pharmacol Ther, 2020, 52(7):1150-1164. |
| [14] | Ahrens EH, Payne MA, Kunkel HG, et al. Primary bi-liary cirrhosis. 1950[J]. Medicine (Baltimore), 1994, 73(5):264-280. |
| [15] | Sherlock S. Primary billiary cirrhosis (chronic intrahepa-tic obstructive jaundice)[J]. Gastroenterology, 1959, 37:574-586. |
| [16] | Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’[J]. Gastroenterology, 2015, 149(6):1627-1629. |
| [17] | Harms MH, Janssen QP, Adam R, et al. Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades[J]. Aliment Pharmacol Ther, 2019, 49(3):285-295. |
| [18] | Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid[J]. Gastroenterology, 2006, 130(3):715-720. |
| [19] | Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J]. Hepatology, 2008, 48(3):871-877. |
| [20] | Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of longterm outcome[J]. J Hepatol, 2011, 55(6):1361-1367. |
| [21] | Yoo JJ, Cho EJ, Lee B, et al. Prognostic value of biochemical response models for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio[J]. Gut Liver, 2018, 12(6):714-721. |
/
| 〈 |
|
〉 |
